Advertisement

Topics

Genkyotex Company Profile

17:36 EDT 19th October 2018 | BioPortfolio

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. A Series C round was closed in 2011 led by Edmond de Rothschild Investment Partners and joined by other new investors Vesalius BioCapital and MP Healthcare Venture Management. Further information can be found at: www.genkyotex.com.


News Articles [14 Associated News Articles listed on BioPortfolio]

Genkyotex (GKTX) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Genkyotex: Edison Investment Research is terminating coverage on Genkyotex (GKTX). Please note you should no longer rely on any previous rese...

Genkyotex: Disclosure of the Total Number of Voting Rights and Shares Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority

(AMF Autorité des Marchés Financiers) Regulatory News: Genkyotex(Paris:GKTX) (Brussels:GKTX): Genkyotex shares ISIN code FR00011790542 Euronext Paris Brussels Date Number of shares making up the s.....

Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

SMB reviewed 77 patients including 60 who have reached 6 weeks of treatment Enrollment in interim analysis cohort of 90 patients has been completed Genkyotex to present corporate overview at two U...

Summary of Genkyotex's Liquidity Contract

Regulatory News: Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Genkyotex (Paris:GKTX) (Brussels:GKTX) shares, effective May 7, 2018, the following resources were listed ...

Genkyotex (GKTX) - Ready to make a dent in the fibrosis market

Edison Investment Research - Pharmaceutical & healthcare - Genkyotex: Genkyotex has initiated a Phase II investigator-sponsored trial in patients with Type 1 diabetes (T1D) and kidney disease (DKD). S...

Genkyotex Announces Completion of Enrollment in Interim Analysis Cohort of Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

The Company confirms interim results in Fall 2018, and final results in the first half of 2019 Regulatory News: Genkyotex (Paris:GKTX) (Brussels:GKTX) (Euronext Paris Brussels: FR00011790542 GKTX)...

Genkyotex cashes in €7.5m

CymaBay, GenKyoTex, And Intercept In PBC: The Clinical Differentiation

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Genkyotex

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...

More Information about "Genkyotex" on BioPortfolio

We have published hundreds of Genkyotex news stories on BioPortfolio along with dozens of Genkyotex Clinical Trials and PubMed Articles about Genkyotex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genkyotex Companies in our database. You can also find out about relevant Genkyotex Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...


Corporate Database Quicklinks



Searches Linking to this Company Record